[12] Metformin: Anchor in the GLP-1 RA Care Continuum Journey The mechanistic, real-world, clinical trials and pharmacovigilance evidence landscape suggests metformin as the potential anchor pharmacological agent across the entire GLP-1 RA care continuum, during therapy and beyond.Table 1 summarises the key potential outcome benefits at each phase
Diabetes, obesity, and insulin resistance in COVID-19: molecular interrelationship and therapeutic implications
The enzyme glutamate-1-semialdehyde aminotransferase (GSAAT) contributes to the rate-limiting step in the synthesis of 5-aminolevulinic acid (ALA)
Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, et al
There is continuous stimulation of pancreatic stellate cells which induces fibrosis, duct obstruction, and acinar atrophy